| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session | 1.427 | GlobeNewswire (Europe) | AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed... ► Artikel lesen | |
| Sa | Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting | 541 | Business Wire |
Phase 3 data from the STOP-HS program demonstrate povorcitinib's substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS).
... ► Artikel lesen | |
| Sa | Galderma SA: AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis | 496 | Business Wire |
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a... ► Artikel lesen | |
| Sa | Bristol Myers Squibb: Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy (xanomeline and trospium chloride) | 413 | Business Wire | High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase... ► Artikel lesen | |
| Sa | Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis | 406 | AFX News | PARIS (dpa-AFX) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials-COAST 1, COAST 2, and SHORE-evaluating amlitelimab, a fully human non-T cell... ► Artikel lesen | |
| 07:22 | Novartis Pharma AG: Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3% | 337 | GlobeNewswire (Europe) | Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| PERRIGO | 8,100 | 0,98 | +12,10 % | 0,29 | 02.03.2026 | |
| NOVO NORDISK | 30,465 | 1,57 | +5,15 % | 7,95 | 27.03.2026 | |
| SANOFI | 81,82 | 3,92 | +4,79 % | 4,12 | 05.05.2026 | |
| BRISTOL-MYERS SQUIBB | 51,10 | 2,16 | +4,23 % | 0,63 | 02.04.2026 | |
| TSUMURA | 19,900 | 0,78 | +3,92 % | 76,00 | 30.03.2026 | |
| NIPPON KAYAKU | 9,700 | 0,33 | +3,40 % | 30,00 | 30.03.2026 | |
| EISAI | 26,000 | 0,87 | +3,35 % | 80,00 | 30.03.2026 | |
| CHUGAI PHARMACEUTICAL | 45,680 | 1,48 | +3,24 % | 66,00 | 29.06.2026 | |
| ONO PHARMACEUTICAL | 13,300 | 0,43 | +3,23 % | 40,00 | 30.03.2026 | |
| GSK | 23,670 | 0,76 | +3,21 % | 0,18 | 19.02.2026 |